Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host
- PMID: 8668850
Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host
Abstract
Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are common causes of respiratory infections in immunocompetent children under the age of 6 years. These viruses belong to a family of enveloped single-stranded RNA viruses, the paramyxoviruses. The clinical manifestations in the normal host range from mild illness to severe croup, bronchiolitis, and pneumonia. After the age of 6 years, reinfections occur, but are characterized by diminishing frequency and severity. In contrast to the normal adult host, severe lower respiratory tract infection can occur in immunocompromised adults as well as children, with significant morbidity and mortality. Similar to the normal host, infection with RSV occurs in epidemics in the winter and spring, while PIV occurs throughout the year. Immunocompromised hosts often have upper respiratory tract symptoms similar to those experienced by normal hosts, as well as a higher incidence of lower respiratory tract symptoms and sinusitis. Lower respiratory tract infection can lead to respiratory failure and death, especially in bone marrow transplant recipients. The diagnosis of RSV and PIV depends on the analysis of specimens obtained from the respiratory tract. Rapid diagnostic tests are readily available for RSV and are less widely used for some of the PIV serotypes. Primary cultures are used for both viruses, but take several days to yield a positive result. Ribavirin, a broad-spectrum antiviral agent, is effective against RSV and PIV in vitro. Clinical trials have shown ribavirin to be of benefit in treating infants infected with RSV. However, clinical trials in immunocompromised patients infected with RSV or PIV have not been carried out. Since infection with RSV and PIV can be severe and life-threatening and treatment with ribavirin is relatively benign, it seems warranted to treat immunocompromised patients infected with RSV or PIV with ribavirin until otherwise proven unwarranted.
Similar articles
-
A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.Transpl Infect Dis. 2010 Feb;12(1):38-44. doi: 10.1111/j.1399-3062.2009.00453.x. Epub 2009 Sep 15. Transpl Infect Dis. 2010. PMID: 19761558
-
Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.Pediatr Infect Dis J. 2007 Dec;26(12):1089-93. doi: 10.1097/INF.0b013e3181343b7e. Pediatr Infect Dis J. 2007. PMID: 18043443
-
Pulmonary infections with respiratory syncytial virus and the parainfluenza viruses.Semin Respir Infect. 1987 Jun;2(2):112-21. Semin Respir Infect. 1987. PMID: 2827280 Review.
-
Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study.Bone Marrow Transplant. 2001 Oct;28(8):759-63. doi: 10.1038/sj.bmt.1703216. Bone Marrow Transplant. 2001. PMID: 11781627
-
Respiratory tract infections caused by respiratory syncytial virus in children. Diagnosis and treatment.Minerva Pediatr. 2001 Apr;53(2):99-106. Minerva Pediatr. 2001. PMID: 11404731 Review.
Cited by
-
Multiple, non-conserved, internal viral ligands naturally presented by HLA-B27 in human respiratory syncytial virus-infected cells.Mol Cell Proteomics. 2010 Jul;9(7):1533-9. doi: 10.1074/mcp.M900508-MCP200. Epub 2010 Jan 15. Mol Cell Proteomics. 2010. PMID: 20081153 Free PMC article.
-
Respiratory syncytial virus (RSV) nonstructural (NS) proteins as host range determinants: a chimeric bovine RSV with NS genes from human RSV is attenuated in interferon-competent bovine cells.J Virol. 2002 May;76(9):4287-93. doi: 10.1128/jvi.76.9.4287-4293.2002. J Virol. 2002. PMID: 11932394 Free PMC article.
-
Oral ribavirin therapy for lower respiratory tract infection of respiratory syncytial virus complicating bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.Int J Hematol. 2011 Jan;93(1):132-4. doi: 10.1007/s12185-010-0756-9. Epub 2011 Jan 5. Int J Hematol. 2011. PMID: 21207211 No abstract available.
-
Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus.Biomedicines. 2021 Sep 7;9(9):1176. doi: 10.3390/biomedicines9091176. Biomedicines. 2021. PMID: 34572362 Free PMC article.
-
Immunoproteomic Lessons for Human Respiratory Syncytial Virus Vaccine Design.J Clin Med. 2019 Apr 10;8(4):486. doi: 10.3390/jcm8040486. J Clin Med. 2019. PMID: 30974886 Free PMC article. Review.